The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, ...

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, ...

Serial CTRS, an AI-powered tool, has been granted FDA breakthrough device designation for classifying patients with NSCLC.

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine ...

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.